Access the full text.
Sign up today, get DeepDyve free for 14 days.
Goldstein (2006)
Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working GroupStroke, 37
A. Kastrati, J. Mehilli, F. Neumann, F. Dotzer, J. Berg, H. Bollwein, Isolde Graf, Maryam Ibrahim, J. Pache, M. Seyfarth, H. Schühlen, J. Dirschinger, P. Berger, A. Schömig (2006)
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.JAMA, 295 13
J. Puma, Lesan Banko, K. Pieper, T. Sacchi, J. O'shea, J. Dery, J. Tcheng (2006)
Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.Journal of the American College of Cardiology, 47 4
G. Stone, B. McLaurin, David Cox, Michel Bertrand, A. Lincoff, Jeffrey Moses, Harvey White, S. Pocock, James Ware, F. Feit, P. Aylward, Angel Cequier, W. Desmet, R. Ebrahimi, M. Hamon, L. Rasmussen, H. Rupprecht, J. Hoekstra, R. Mehran, E. Ohman (2006)
Bivalirudin for patients with acute coronary syndromes.The New England journal of medicine, 355 21
Kleiman Kleiman, Lincoff Lincoff, Flaker Flaker (2000)
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromesCirculation, 101
P. Ho, E. Peterson, Li Wang, D. Magid, S. Fihn, G. Larsen, R. Jesse, J. Rumsfeld (2008)
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.JAMA, 299 5
S. Kunapuli, Z. Ding, R. Dorsam, Soochong Kim, S. Murugappan, T. Quinton (2003)
ADP receptors--targets for developing antithrombotic agents.Current pharmaceutical design, 9 28
A. Lincoff, N. Kleiman, D. Kereiakes, F. Feit, J. Bittl, J. Jackman, I. Sarembock, D. Cohen, D. Spriggs, R. Ebrahimi, G. Keren, J. Carr, E. Cohen, A. Betriu, W. Desmet, W. Rutsch, R. Wilcox, P. Feyter, A. Vahanian, E. Topol (2004)
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.JAMA, 292 6
E. Boersma, K. Akkerhuis, P. Théroux, R. Califf, E. Topol, M. Simoons (1999)
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.Circulation, 100 20
G. Stone, M. Bertrand, J. Moses, E. Ohman, A. Lincoff, J. Ware, S. Pocock, B. McLaurin, D. Cox, M. Jafar, H. Chandna, F. Hartmann, F. Leisch, R. Strasser, M. Desaga, T. Stuckey, R. Zelman, I. Lieber, D. Cohen, R. Mehran, H. White, for Investigators (2007)
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.JAMA, 297 6
J. Ryan, E. Peterson, A. Chen, M. Roe, E. Ohman, C. Cannon, P. Berger, J. Saucedo, E. DeLong, S. Normand, C. Pollack, D. Cohen (2005)
Optimal Timing of Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) RegistryCirculation, 112
A. Hirsch, Z. Haskal, N. Hertzer, C. Bakal, M. Creager, J. Halperin, L. Hiratzka, William Murphy, J. Olin, J. Puschett, K. Rosenfield, D. Sacks, J. Stanley, L. Taylor, C. White, John White, Rodney White, E. Antman, Sidney Smith, C. Adams, Jeffrey Anderson, D. Faxon, V. Fuster, R. Gibbons, S. Hunt, A. Jacobs, Rick Nishimura, J. Ornato, R. Page, B. Riegel (2006)
ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and InterventJournal of vascular and interventional radiology : JVIR, 17 9
S. Manoukian, F. Feit, R. Mehran, Michele Voeltz, R. Ebrahimi, M. Hamon, G. Dangas, A. Lincoff, H. White, J. Moses, S. King, E. Ohman, G. Stone (2007)
Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.Journal of the American College of Cardiology, 49 12
S. Steinhubl, P. Berger, D. Brennan, E. Topol (2006)
Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention.Journal of the American College of Cardiology, 47 5
I. Müller, M. Seyfarth, S. Rüdiger, B. Wolf, G. Pogátsa-Murray, A. Schömig, M. Gawaz (2001)
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placementHeart, 85
P. Savi, J. Herbert (2005)
Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.Seminars in thrombosis and hemostasis, 31 2
D. Clement (1996)
A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 348
Raymond McKay, William Boden (2001)
Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials.Current opinion in cardiology, 16 6
T. Jernberg, C. Payne, K. Winters, C. Darstein, J. Brandt, J. Jakubowski, H. Naganuma, A. Siegbahn, L. Wallentin (2006)
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.European heart journal, 27 10
S. King, Sidney Smith, J. Hirshfeld, A. Jacobs, D. Morrison, David Williams, T. Feldman, M. Kern, W. O’Neill, H. Schaff, P. Whitlow, C. Adams, Jeffrey Anderson, C. Buller, M. Creager, S. Ettinger, J. Halperin, S. Hunt, H. Krumholz, F. Kushner, B. Lytle, Rick Nishimura, R. Page, B. Riegel, L. Tarkington, C. Yancy (2008)
2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines.Journal of the American College of Cardiology, 51 2
P. Gurbel, K. Bliden, K. Hayes, Jason Yoho, W. Herzog, U. Tantry (2005)
The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.Journal of the American College of Cardiology, 45 9
L. Goldstein, R. Adams, M. Alberts, L. Appel, L. Brass, C. Bushnell, A. Culebras, T. DeGraba, P. Gorelick, J. Guyton, R. Hart, G. Howard, M. Kelly‐Hayes, J. Nixon, R. Sacco (2006)
Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, PCirculation, 113 24
Gustavo Oliveira, E. Crespo, R. Becker, E. Honeycutt, C. Abrams, K. Anstrom, P. Berger, L. Davidson-Ray, E. Eisenstein, N. Kleiman, D. Moliterno, S. Moll, L. Rice, J. Rodgers, S. Steinhubl, V. Tapson, E. Ohman, C. Granger (2008)
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.Archives of internal medicine, 168 1
Ajay Kirtane, G. Piazza, S. Murphy, D. Budiu, David Morrow, David Cohen, E. Peterson, N. Lakkis, Howard Herrmann, T. Palabrica, C. Gibson (2006)
Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial.Journal of the American College of Cardiology, 47 12
P. Fishman, F. Shofer, Jennifer Robey, Kara Zogby, P. Reilly, C. Branas, J. Pines, J. Hollander (2006)
The impact of trauma activations on the care of emergency department patients with potential acute coronary syndromes.Annals of emergency medicine, 48 4
D. Morrow, E. Antman, S. Snapinn, C. McCabe, P. Théroux, E. Braunwald (2002)
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.European heart journal, 23 3
J. Brandt, C. Payne, S. Wiviott, G. Weerakkody, N. Farid, D. Small, J. Jakubowski, H. Naganuma, K. Winters (2007)
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.American heart journal, 153 1
C. Pollack, E. Braunwald (2008)
2007 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice.Annals of emergency medicine, 51 5
Chadwick Miller, C. Lindsell, S. Khandelwal, A. Chandra, C. Pollack, B. Tiffany, J. Hollander, W. Gibler, J. Hoekstra (2004)
Is the initial diagnostic impression of "noncardiac chest pain" adequate to exclude cardiac disease?Annals of emergency medicine, 44 6
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 357 20
G. Stone, James Ware, Michel Bertrand, A. Lincoff, Jeffrey Moses, E. Ohman, Harvey White, F. Feit, Antonio Colombo, B. McLaurin, David Cox, S. Manoukian, M. Fahy, Tim Clayton, R. Mehran, S. Pocock, for Investigators (2007)
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.JAMA, 298 21
J. Bassand (2007)
Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm.European heart journal, 28 11
N. Kleiman, A. Lincoff, G. Flaker, K. Pieper, R. Wilcox, L. Berdan, T. Lorenz, D. Cokkinos, M. Simoons, E. Boersma, E. Topol, R. Califf, R. Harrington (2000)
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.Circulation, 101 7
P. Gurbel, K. Bliden, W. Samara, Jason Yoho, K. Hayes, M. Fissha, U. Tantry (2005)
Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.Journal of the American College of Cardiology, 46 10
C. Cannon, S. Husted, R. Harrington, B. Scirica, H. Emanuelsson, G. Peters, R. Storey (2007)
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.Journal of the American College of Cardiology, 50 19
F. Feit, Michele Voeltz, M. Attubato, A. Lincoff, Derek Chew, J. Bittl, E. Topol, S. Manoukian (2007)
Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial.The American journal of cardiology, 100 9
P. Gurbel, K. Bliden, K. Zaman, Jason Yoho, K. Hayes, U. Tantry (2005)
Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) StudyCirculation, 111
R. Dorsam, S. Kunapuli (2004)
Central role of the P2Y12 receptor in platelet activation.The Journal of clinical investigation, 113 3
Kastrati Kastrati, Mehilli Mehilli, Neumann Neumann (2006)
Intracoronary stenting and antithrombotic regimen: Rapid early action for coronary treatment 2 (ISAR‐REACT 2)JAMA, 295
A. Connor (2002)
The way I see it: House officers need formal career developmentBMJ, 324
C. Baigent, C. Sudlow, R. Collins, R. Peto, Antithromboci Collaborat (2002)
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ : British Medical Journal, 324
D. Fintel, G. Ledley (2000)
Management of patients with non—ST‐segment elevation acute coronary syndromes: Insights from the pursuit trialClinical Cardiology, 23
S. Yusuf, S. Mehta, S. Chrolavicius, Rizwan Afzal, J. Pogue, C. Granger, A. Budaj, R. Peters, J. Bassand, L. Wallentin, C. Joyner, K. Fox (2006)
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.The New England journal of medicine, 354 14
A. Lincoff, J. Bittl, R. Harrington, F. Feit, N. Kleiman, J. Jackman, I. Sarembock, D. Cohen, D. Spriggs, R. Ebrahimi, G. Keren, J. Carr, E. Cohen, A. Betriu, W. Desmet, D. Kereiakes, W. Rutsch, R. Wilcox, P. Feyter, A. Vahanian, E. Topol (2003)
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.JAMA, 289 7
S. Husted, H. Emanuelsson, S. Heptinstall, P. Sandset, M. Wickens, G. Peters (2006)
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.European heart journal, 27 9
Anderson (2007)
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction): Developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic SurgeonsJ Am Coll Cardiol, 50
J. Bassand, C. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernández‐Avilés, K. Fox, D. Hasdai, E. Ohman, L. Wallentin, W. Wijns (2007)
[Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes].Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 27 9
J. Barrabés, D. Garcia-Dorado, M. Mirabet, R. Lidón, B. Soriano, M. Ruiz-Meana, P. Pizcueta, J. Blanco, Y. Puigfel, J. Soler‐Soler (2002)
Lack of effect of glycoprotein IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs.Journal of the American College of Cardiology, 39 1
C. Grines, Robert Bonow, Donald Casey, Timothy Gardner, Peter Lockhart, D. Moliterno, Patrick O'Gara, Patrick Whitlow (2007)
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American DCirculation, 115 6
Fraker (2007)
2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable AnginaJ Am Coll Cardiol, 40
Epilog Investigators (1997)
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.The New England journal of medicine, 336 24
J. Saw, A. Lincoff, W. Desmet, A. Betriu, W. Rutsch, R. Wilcox, N. Kleiman, K. Wolski, E. Topol (2004)
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.Journal of the American College of Cardiology, 44 6
S. Bertuglia, A. Giusti (2002)
Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusionBMC Cardiovascular Disorders, 2
E. Karvouni, D. Katritsis, J. Ioannidis (2003)
Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.Journal of the American College of Cardiology, 41 1
Marc Cohen, J. Díez, G. Levine, J. Ferguson, D. Morrow, S. Rao, J. Zidar (2007)
Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III.The Journal of invasive cardiology, 19 12
M. McDaniel, R. Fazel, Michele Voeltz, F. Feit, A. Lincoff, S. Manoukian (2006)
Abstract 3432: Eptifibatide plus Heparin Increases the Risk of Major and Minor Hemorrhagic Complications Compared to Bivalirudin in Patients with Normal Renal Function Undergoing Percutaneous Coronary InterventionCirculation, 114
C. Gibson, D. Morrow, S. Murphy, T. Palabrica, L. Jennings, P. Stone, Henry Lui, T. Bulle, N. Lakkis, R. Kovach, D. Cohen, P. Fish, C. Mccabe, E. Braunwald (2006)
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.Journal of the American College of Cardiology, 47 12
U. Tantry, K. Bliden, P. Gurbel (2005)
Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation.Journal of the American College of Cardiology, 46 9
M. Leon, D. Baim, J. Popma, P. Gordon, D. Cutlip, K. Ho, A. Giambartolomei, D. Diver, D. Lasorda, David Williams, S. Pocock, R. Kuntz (1998)
A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingThe New England Journal of Medicine, 339
A. Greenbaum, C. Grines, J. Bittl, R. Becker, D. Kereiakes, I. Gilchrist, Jane Clegg, Jill Stankowski, D. Grogan, R. Harrington, H. Emanuelsson, W. Weaver (2006)
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.American heart journal, 151 3
P. Gurbel, K. Bliden, K. Guyer, Peter Cho, K. Zaman, R. Kreutz, A. Bassi, U. Tantry (2005)
Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.Journal of the American College of Cardiology, 46 10
P. Gurbel, K. Bliden, B. Hiatt, C. O'connor (2003)
Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet ReactivityCirculation, 107
S. Fugate, L. Cudd (2006)
Cangrelor for Treatment of Coronary ThrombosisAnnals of Pharmacotherapy, 40
K. Alexander, A. Chen, M. Roe, L. Newby, C. Gibson, Nancy Allen-LaPointe, C. Pollack, W. Gibler, E. Ohman, E. Peterson (2005)
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.JAMA, 294 24
With the availability of new data and the recent release of new European and US guidelines, contemporary care paradigms for the treatment of patients with non‐ST‐elevation acute coronary syndromes (NSTE ACS), including those undergoing percutaneous coronary intervention, are likely to undergo substantial changes. In recognition of this shifting landscape as well as the impact of new guidelines on care models for the treatment of patients with NSTE ACS, a roundtable was convened on October 25, 2007, to discuss the implications of these changes. The purpose of this review is to summarize the presentations and subsequent discussions from the roundtable, which examined the guidelines and evidence from a variety of perspectives, and to explore the best ways to incorporate new treatment paradigms into everyday clinical care. The multiple viewpoints expressed by the roundtable attendees illustrate the recognition that at this point, consensus has not been reached on the optimum algorithm for treatment of these patients. This article focuses on issues discussed during the roundtable from the perspective of the practicing cardiologist.
Journal of Interventional Cardiology – Wiley
Published: Aug 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.